Skip to main content

Emerald Health Therapeutics Inc (EMH-X) Quote

Unchecking box will stop auto data updates
TSX Venture Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 0.890
Day High 0.930
Open:0.900
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Emerald Health Therapeutics Inc is a vertically integrated Canadian licensed producer of cannabis, focused on developing proprietary, cannabis products for medical and adult-use customers. The company's Pure Sunfarms joint venture has two 1.1 M sf greenhouses. The Verdelite operation in Quebec is an approx. 88,000 sf indoor facility licensed for cultivation and production. It has contracted around 1000 acres of hemp in 2019 to 2022. Through strategic partnerships, the company has secured industrial extraction, softgel encapsulation and formulation technology for innovative product development.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Emerald Health Therapeutics Expands Adult-Use Cannabis Product Distribution to Nova Scotia
- GlobeNewswire - Tue Oct 22, 6:00AM CDT
GlobeNewswire - CMTX
Tue Oct 22, 6:00AM CDT
Emerald Health Therapeutics, Inc. ("Emerald") (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first shipment of premium cannabis products to the Nova Scotia Liquor Corporation (NSLC) for the adult-use market. This first shipment consisted of Emerald's high potency SYNC 25 CBD oil and White Rhino cannabis flower, two of Emerald's best-selling products in other markets.
Celebrity Endorsements Drive the CBD Industry to New Heights
- PR Newswire - Mon Oct 21, 8:00AM CDT
PR Newswire - CMTX
Mon Oct 21, 8:00AM CDT
Whereas cannabis used to be a taboo in most societies, now, the plant is becoming a topic that is publicly endorsed by millions. A handful of celebrities have even done their part to help bring the industry into the global spotlight with their support. Influential figures such as Seth Rogan, Snoop Dogg, Olivia Wilde, Jay Z, Danny DeVito, Wiz Khalifa, and Willie Nelson are just some of the outspoken celebrities helping to put cannabis on the map. Generally, most celebrities have either decided to create their own brand or invest in a cannabis-based operator. For instance, Willie Nelson operates his own cannabis company called "Willie's Reserve." On his site, he sells a variety of products such as pre-rolled joints, dried flower, edibles, and oil concentrates. However, after the passage of the U.S. Farm Bill, many decided to create a CBD brand. Notably, former New England Patriots tight end Rob Gronkowski partnered with Abacus Health to launch CBDMedic, a clinical retailer to help with pain management. Moreover, Gwyneth Paltrow's lifestyle brand, Goop, announced that it will offer CBD beauty products on its online store, including CBD-based products such as tinctures, lotions, and edibles. Overall, the CBD marketplace is much more attractive because it is legal in the U.S. and many other countries for medicinal purposes. In the U.S., health officials ultimately legalized CBD because it does not cause psychotropic effects on the consumer, unlike its THC counterpart. However, regulators have noted that more research and clinical trials are still needed to further understand the efficacy of CBD, as well as its safety. Nonetheless, as research continues to ramp up, industry experts believe that CBD is the next upcoming and disruptive market. As a result, by 2024, the cannabis market is expected to reach USD 89.1 Billion from USD 14.5 Billion in 2018, according to Mordor Intelligence. Additionally, the market is expected to register a CAGR of 37% during the forecast period from 2019 to 2024. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Harvest Health & Recreation, Inc. (OTC: HRVSF) (CSE: HARV), KushCo Holdings, Inc. (OTC: KSHB), Emerald Health Therapeutics Inc. (OTC: EMHTF) (TSX-V: EMH)
Emerald Health Therapeutics' Quebec Premium Cannabis Operation Receives Sale License Amendment, Allowing Direct Sales of Branded Products
- GlobeNewswire - Wed Oct 16, 6:02AM CDT
GlobeNewswire - CMTX
Wed Oct 16, 6:02AM CDT
Emerald Health Therapeutics' ("Emerald")(TSXV: EMH; OTCQX: EMHTF) wholly-owned production facility, Verdelite, in St. Eustache, Quebec, has received from Health Canada its license amendment permitting it to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada. To date, Verdelite has been packaging product under the Emerald brand. Moving forward, its marketing strategy will evolve and focus on building multiple differentiated brands, with a unique Quebec identity, targeting consumers seeking premium cannabis for adult use as well as health and wellness benefits.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.760 +21.05% increase
on 10/16/19
Period Open:1.600
Price movement based on the high, low and last over the given period.
1.630 -43.56% decrease
on 09/24/19
-0.680 (-42.50%) decrease
since 09/23/19
3-Month 0.760 +21.05% increase
on 10/16/19
Period Open:1.950
Price movement based on the high, low and last over the given period.
2.650 -65.28% decrease
on 08/06/19
-1.030 (-52.82%) decrease
since 07/23/19
52-Week 0.760 +21.05% increase
on 10/16/19
Period Open:3.380
Price movement based on the high, low and last over the given period.
5.250 -82.48% decrease
on 11/08/18
-2.460 (-72.78%) decrease
since 10/23/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).